The burden and unique patterns of extraintestinal manifestations in Chinese inflammatory bowel disease: a nationwide multicenter investigation Authors: Liuqing Zhao, Zhenzhen Fan, Jindan He, Lianlian Tian, Jun Shen, Hongliang Gao, Yanjun Chen, Xiaojing Zhao, Yan-Bo Yu, Yanyun Fan, Haitao Shi, Hailong Cao, Linglin Tian, Jie Liang Published: 2026 ABSTRACT AbstractExtraintestinal manifestations (EIMs) are a significant disease burden in inflammatory bowel disease (IBD). However, large-scale epidemiological data from the Chinese population remain scarce. This nationwide, multicenter, retrospective cross-sectional study included 2,252 adult IBD inpatients from 10 clinical centers. Data on demographics, clinical features, and EIMs were collected and analyzed using descriptive statistics and logistic regression. Of the 2252 patients, 384 (17.1%) reported at least one EIM. Among these, data on temporal sequence were available for 310 patients, of whom 70 (22.6%) developed their first EIM before the onset of intestinal symptoms. The overall prevalence of EIMs was significantly higher in Crohn’s disease (CD) than in ulcerative colitis (UC) (20.5% vs. 15.4%, P = 0.003). Joint manifestations (10.0%) and aphthous ulcers (5.5%) were most common, with aphthous ulcers significantly more frequent in CD (11.2% vs. 2.8%, P < 0.001). The prevalence of classic EIMs such as arthritis/arthralgia (8.0%), uveitis (0.5%), and erythema nodosum (0.9%) fell within the low-to-mid range of global reports. Significant co-occurrence was observed among EIMs. For example, arthritis/arthralgia showed strong associations with uveitis (OR = 31.88) and erythema nodosum (OR = 13.34). Analysis of medication history revealed higher use of infliximab in patients with arthritis/arthralgia (47.0%) and pyoderma gangrenosum (71.4%), and frequent glucocorticoid use in those with venous thromboembolism (72.4%). In this inpatient-based cohort, the lower prevalence of classic EIMs in Chinese IBD patients may reflect clinical underdetection or genuine epidemiological differences. EIMs can precede intestinal symptoms and influence each other, underscoring the need for proactive, systematic assessment in clinical practice.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s10238-026-02240-1.Keywords: Inflammatory bowel disease, Extraintestinal manifestations, Prevalence, Crohn’s disease, Ulcerative colitis, Treatment patterns Introduction Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is a complex disorder characterized by chronic, relapsing inflammation of the gastrointestinal tract. Its pathogenesis is multifactorial, involving a complex interplay of genetic susceptibility, environmental factors, gut microbiota dysbiosis, and abnormal immune responses [1]. Traditionally, the management of IBD has primarily focused on controlling intestinal inflammation, promoting mucosal healing, and alleviating gastrointestinal symptoms. However, with the deepening of research, IBD is now being redefined as a systemic immune-mediated disease whose impact extends far beyond the digestive tract. Extraintestinal manifestations (EIMs) are considered inflammatory lesions outside the gut in IBD patients. Their pathogenesis is not singular; they may represent a systemic extension of the intestinal immune response or share genetic predispositions and environmental triggers with IBD itself, and they do not always parallel intestinal inflammatory activity [2]. EIMs can affect almost all organ systems, ranging from the most commonly involved musculoskeletal system—such as arthritis and sacroiliitis—to the skin and mucosa, with manifestations including erythema nodosum, pyoderma gangrenosum, and aphthous ulcers. EIMs also extend to ocular involvement, such as uveitis and scleritis; hepatobiliary involvement, as seen in primary sclerosing cholangitis; and even hematological complications like venous thromboembolism [3]. These EIMs contribute significantly to the IBD disease burden, severely impacting patients’ quality of life, work capacity, and mental health, but are also key factors leading to poor prognosis and increased healthcare costs [4]. Research on EIMs in IBD has accumulated substantial progress over time. Existing data show that the overall prevalence of EIMs ranges between 15% and 50%. This variation in reported rates is related not only to diagnostic criteria but also reflects heterogeneity across different regions and populations [5–9] .Regarding risk factors, a large European cohort study identified CD, female sex, history of IBD-related surgery, smoking, older age at diagnosis, and family history of IBD as independent risk factors for the development of EIMs [10]. In terms of the timing of onset, a Greek multicenter cohort study found that approximately 38.6% of patients were diagnosed with an EIM before their IBD diagnosis [11]. Furthermore, a Swiss cohort study demonstrated that IBD patients can experience up to five different EIMs simultaneously or sequentially over their lifetime, indicating the cumulative and diverse clinical nature of EIMs [12]. Although the incidence of IBD continues to rise in Asia [13], reports on EIMs remain relatively limited. Current understanding of the epidemiology and risk factors of EIMs is largely based on studies in Western populations. While some related research exists in Asia, there is still a lack of systematic, large-scale, multicenter cohort data from China. Therefore, this study aims to achieve the following objectives through a large, multicenter IBD cohort in China: first, to systematically characterize the disease spectrum and prevalence features of EIMs in the Chinese population and conduct cross-population comparisons with recent existing data; second, to comprehensively document the clinical medication history of patients with different EIM subtypes and analyze differences in treatment patterns. This study hopes to provide detailed evidence from the Chinese population to enrich the cross-regional understanding of IBD-related EIMs. Methods Study design and participants This multicenter, retrospective, cross-sectional study was led by the First Affiliated Hospital of the Air Force Medical University and conducted in collaboration with nine other major medical centers across China: the Second Affiliated Hospital of Xi’an Jiaotong University, the First Affiliated Hospital of Xinjiang Medical University, Zhongshan Hospital Affiliated to Xiamen University, the First Affiliated Hospital of Soochow University, Renji Hospital (Shanghai Jiao Tong University School of Medicine), Tianjin Medical University General Hospital, Qilu Hospital of Shandong University, Jiangsu Provincial People’s Hospital, and the First Hospital of Shanxi Medical University. Consecutive adult patients hospitalized between January 1, 2020, and August 31, 2025, with a primary diagnosis of IBD—either UC or CD—meeting the Chinese Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2023) were included. Exclusion criteria comprised admission outside the study period, substantial missing clinical data (demographics, disease classification, EIM records, treatment history), or a diagnosis of indeterminate colitis. Of 2,762 screened cases, 2,252 eligible patients were finally analyzed. Data collection Data collection comprehensively covered demographic characteristics; clinical features including age at diagnosis, disease duration, maximum disease activity [mild/moderate/severe] based on clinical and endoscopic assessment during hospitalization or follow-up, Montreal classification for CD [location L1–L4, behavior B1–B3, age at diagnosis A1–A3] and UC [extent E1–E3], perianal disease, appendectomy history, and IBD-related surgery history; lifestyle factors (smoking, alcohol use); EIMs across joints (arthritis/arthralgia, ankylosing spondylitis [AS], sacroiliitis), skin/mucosa (erythema nodosum [EN], pyoderma gangrenosum [PG], psoriasis, aphthous ulcers), eyes (uveitis, conjunctivitis, central retinal vein occlusion), hepatobiliary system (primary sclerosing cholangitis [PSC], autoimmune hepatitis [AIH]), and venous thromboembolic events (VTE), diagnosed via specialist consultation or standard criteria. Aphthous ulcers were included as an EIM based on standard clinical practice, although their classification remains debated in the literature. To address this ambiguity, we also reported EIM prevalence excluding aphthous ulcers (as “EIMs other than aphthous ulcers” in Table 2).Treatment history including systemic glucocorticoids, immunosuppressants (azathioprine, 6-mercaptopurine, methotrexate), biologics (infliximab [IFX], adalimumab [ADA], ustekinumab [UST], vedolizumab [VDZ]), and JAK inhibitors; and, for EIM-positive patients, temporal sequencing of EIM onset relative to intestinal symptom debut (preceding, simultaneous, or following). Table 2Frequency and type of extraintestinal manifestationsIBD(n = 2252)UC(n = 1531)CD(n = 721)χ2PAll extraintestinal manifestations, n(%)384(17.1)236(15.4)148(20.5)9.0570.003Extraintestinal manifestations other than aphthous ulcers, n(%)298(13.23)213(13.9)85(11.8)1.9250.165Joint, n(%)226(10.0)161(11.0)65(9.0)1.2230.269Arthritis/arthralgia181(8.0)134(8.8)47(6.5)3.3540.067Ankylosing spondylitis38(1.7)26(1.7)12(1.7)0.0030.954Sacroiliitis27(1.2)15(1.0)12(1.7)1.9390.164Eye, n(%)21(0.9)18(1.2)3(0.4)3.0620.080Uveitis11(0.5)9(0.6)2(0.3)-0.508Conjunctivitis8(0.4)7(0.6)1(0.1)-0.420Central retinal vein occlusion2(0.1)2(0.1)0-> 0.999Skin, n(%)46(2.0)30(2.0)16(2.2)0.1650.184Pyoderma gangrenosum7(0.3)7(0.6)0-0.105Erythema nodosum21(0.9)13(0.9)8(1.1)0.3600.549Psoriasis18(0.8)10(0.7)8(1.1)1.2880.256Aphthous ulcers, n(%)124(5.5)43(2.8)81(11.2)66.881< 0.001Hepatobiliary, n(%)18(0.8)15(1.0)3(0.4)1.9640.161Primary sclerosing cholangitis11(0.5)9(0.6)2(0.3)-0.508Autoimmune hepatitis8(0.4)7(0.5)1(0.1)-0.420Venous thromboembolic events, n(%)29(1.3)23(1.5)6(0.8)1.7320.188 Frequency and type of extraintestinal manifestations Statistical analysis All statistical analyses were performed using SPSS software (version 26.0). Normally distributed continuous variables are presented as mean ± standard deviation, while non-normally distributed variables are described as median (M) with interquartile range (Q₁, Q₃). Categorical variables are presented as frequency (n) and percentage (%). The prevalence of EIMs was calculated and described as the number of cases and percentage of the total population. For group comparisons, continuous variables were analyzed using independent samples t-test or Mann-Whitney U test, and categorical variables using chi-square test or Fisher’s exact test. To analyze factors associated with EIMs, univariate logistic regression (P < 0.05 for entry) was first performed separately for CD and UC patients to screen variables, followed by multivariate logistic regression (forward stepwise method) to identify independent associated factors. Results are presented as adjusted odds ratios (aOR) with 95% confidence intervals (CI). To explore co-occurrence relationships between different EIMs, chi-square tests or Fisher’s exact tests were used to assess associations, and odds ratios (OR) with 95% CI were calculated for associated pairs to quantify the strength of co-occurrence. Additionally, descriptive statistical analysis was performed on the medication profiles of patients with different EIM types. All tests were two-sided, and a P-value < 0.05 was considered statistically significant. Given the cross-sectional and retrospective design, all associations reported in this study reflect statistical coexistence rather than temporal or causal relationships. Results Patients baseline characteristics A total of 2,252 patients with IBD were included, consisting of 1,531 with UC and 721 with CD. The median age at diagnosis was 42 years (IQR: 30.0–53.0) for UC patients and 32 years (IQR: 23.0–46.0) for CD patients. Both groups were predominantly male (UC: 59.5%; CD: 60.2%). Regarding pharmacological treatment, glucocorticoids were used by 42.7% of UC patients and 20.8% of CD patients. Use of biologics was more common in CD patients, with IFX administered in 35.2% and UST in 34.5%. With respect to surgical history, 25.2% of CD patients had undergone IBD-related surgery, compared to 2.5% of UC patients. Further demographic and clinical characteristics are summarized in Table 1. Table 1Baseline characteristics of 2252 patients with inflammatory bowel diseaseDisease characteristicsUlcerative colitis(n = 1531)Crohn’s disease(n = 721)Age at diagnosis in years, M (Q₁, Q₃)42.0(30.0,53.0)32.0(23.0,46.0)Duration of disease in years, M (Q₁, Q₃)3.0(0.0,7.0)2.0(0.0,5.0)Age, M (Q₁, Q₃)48.0(36.0,59.0)36.0(26.0,50.3)Gender, n(%)Male911(59.5)434(60.2)Female620(40.5)287(39.8)History of smoking, n(%)258(16.9)78(10.8)History of alcohol consumption, n(%)239(15.6)65(9.0)History of appendicitis surgery, n(%)20(1.3)44(6.1)Treatment history, n(%)Glucocorticoids653(42.7)150(20.8)Immunosuppressants122(8.0)79(11.0)Infliximab407(26.6)254(35.2)Adalimumab26(1.7)76(10.5)Ustekinumab6(0.4)249(34.5)Vedolizumab375(24.5)33(4.6)JAK Inhibitors32(2.1)4(0.6)History of IBD-related surgeries38(2.5)182(25.2) Baseline characteristics of 2252 patients with inflammatory bowel disease Prevalence and international comparison of EIMs A retrospective analysis of 2,252 IBD patients revealed that 384 patients (17.1%) experienced at least one EIM (Table 2). Among various EIM types, joint manifestations were the most common, with an overall occurrence of 10.0%, comprising arthritis/arthralgia (8.0%), AS (1.7%), and sacroiliitis (1.2%). Oral aphthous ulcers ranked second in frequency (5.5%), followed by skin manifestations (2.0%, including EN (0.9%), psoriasis (0.8%), and PG (0.3%)), ocular manifestations (0.9%, including uveitis (0.5%) and conjunctivitis (0.4%)), and hepatobiliary manifestations (0.8%, including PSC (0.5%) and AIH (0.4%)). Additionally, the prevalence of VTE was 1.3%. Analysis by disease subtype indicated that the overall prevalence of EIMs was significantly higher in CD patients than in UC patients (20.5% vs. 15.4%, P = 0.003). Notably, the occurrence of oral aphthous ulcers was significantly more frequent in CD patients (11.2% vs. 2.8%, P < 0.001), while the distribution of most other EIMs showed no statistically significant differences between the two groups. Comparison with similar studies from other countries and regions demonstrated that the prevalence of the vast majority of EIMs in this cohort falls within the low to moderate range of international reports [5, 11], 14– [20] (Appendix). Among these, the prevalence of aphthous ulcers was relatively high, making it one of the most common EIM types in this study. Among joint manifestations, the prevalence of arthritis/arthralgia (8.0%), sacroiliitis (1.2%), and AS (1.7%) were all significantly lower than those reported in most European and American studies, although generally higher than rates observed in some Asian countries (such as South Korea and Japan). Overall, these prevalences remained at the low to lower-middle range of the international spectrum. The prevalences of uveitis (0.5%) and PSC (0.5%) were lower than those reported in European and American studies (such as Italy and the USA) and were generally consistent with the rates observed in Asian countries, placing them at the lower end of the international range. The prevalence of VTE (1.3%) was comparable to some Asian and European countries (such as Japan and Canada), lower than high-prevalence nations, and within the mid-range internationally. Regarding skin manifestations, the prevalences of EN (0.9%) and PG (0.3%) were substantially lower than those reported in European and American studies Temporal relationship between EIMs and intestinal symptoms Among the 384 patients with EIMs, 310 had documented temporal relationships between EIM onset and intestinal symptom onset (Fig. 1). The remaining 74 patients (19.3%) were excluded from this analysis because their EIMs were diagnosed at outside hospitals and the exact onset date could not be reliably verified. Of the 310 patients, 182 (58.7%) developed EIMs after intestinal symptom onset, 58 (18.7%) had simultaneous onset, and 70 (22.6%) experienced EIMs before intestinal symptoms appeared. Temporal distribution of EIMs relative to intestinal symptom onset Distribution patterns of EIMs in IBD The distribution of EIMs showed a distinct pattern of progressive decline as the number of EIM types increased (Fig. 2). Patients experiencing only one EIM type represented the largest proportion (13.3%). The prevalence of patients who had developed two distinct EIMs decreased significantly to 3.1% overall (UC: 3.0%, CD: 3.3%). Those with three EIMs were uncommon (0.6%-0.7%), while patients who had presented with four different EIMs were exceptionally rare (≤ 0.1%). Percentage distribution of IBD patients by number of EIMs Clinical correlates of EIMs in UC Univariate analysis in UC patients (Supplementary Table 1) showed significant associations between EIMs and maximum disease activity (P = 0.015), longer disease duration (P < 0.001), history of appendectomy (P = 0.033), as well as use of glucocorticoids (P = 0.013), immunosuppressants (P < 0.001), IFX (P < 0.001), and ADA (P = 0.006). Multivariate analysis further confirmed that longer disease duration (OR = 1.036, 95% CI: 1.013–1.060, P = 0.002), history of appendectomy (OR = 2.776, 95% CI: 1.034–7.454, P = 0.043), use of immunosuppressants (OR = 1.756, 95% CI: 1.093–2.820, P = 0.020), and use of IFX (OR = 3.431, 95% CI: 2.542–4.631, P < 0.001) were independent clinical correlates of EIMs. Clinical correlates of EIMs in CD Univariate analysis in CD patients (Supplementary Table 2) showed significant associations between EIMs and smoking history (P = 0.018), alcohol consumption history (P = 0.032), maximum disease activity (P = 0.009), older age at diagnosis (P = 0.003), history of appendectomy (P = 0.022), longer disease duration (P = 0.012), as well as use of glucocorticoids (P < 0.001), immunosuppressants (P < 0.001), ADA (P < 0.001), UST (P = 0.006), and VDZ (P = 0.021). Multivariate logistic regression analysis further indicated that after adjusting for other variables, older age at diagnosis (OR = 1.017, 95% CI: 1.003–1.030, P = 0.015), use of glucocorticoids (OR = 1.777, 95% CI: 1.125–2.807, P = 0.014), use of immunosuppressants (OR = 2.474, 95% CI: 1.413–4.327, P = 0.002), and use of ADA (OR = 2.478, 95% CI: 1.442–4.257, P = 0.001) were independent clinical correlates of EIMs. Additionally, compared to mild disease activity, patients whose maximum disease activity was classified as moderate showed a significantly lower likelihood of having EIMs (OR = 0.458, 95% CI: 0.222–0.944, P = 0.034). Associations between different EIMs A total of 11 EIM types were included in the co-occurrence analysis, resulting in 55 pairwise comparisons. To account for multiple comparisons, we applied the Bonferroni correction, setting the significance threshold at P < 0.0009 (0.05/55). After correction, only the following associations remained statistically significant: arthritis/arthralgia with sacroiliitis (OR = 13.271, 95% CI: 6.137–28.697, P < 0.001), arthritis/arthralgia with EN (OR = 13.336, 95% CI: 5.584–31.849, P < 0.001), arthritis/arthralgia with aphthous ulcers (OR = 4.179, 95% CI: 2.683–6.508, P < 0.001), arthritis/arthralgia with uveitis (OR = 31.877, 95% CI: 8.381-121.245, P < 0.001), and arthritis/arthralgia with VTE (OR = 6.316, 95% CI: 2.891–13.798, P < 0.001). Associations involving rarer EIMs (such as pyoderma gangrenosum, n = 7; central retinal vein occlusion, n = 2) did not remain significant after Bonferroni correction and should be interpreted with caution due to small sample sizes (Table 3 footnotes). Table 3Analysis of Associations Between Different EIMsOR [95% CI][P-value]SacroiliitisErythema nodosumAphthous ulcerUveitisVenous thromboembolic eventsArthritis/arthralgia13.271[6.137–28.697][P < 0.001] *13.336[5.584–31.849][P < 0.001] *4.179[2.683–6.508][P < 0.001] *31.877[8.381-121.245][P < 0.001] *6.316[2.891–13.798][P < 0.001] *Sacroiliitis-4.022[1.497–10.808][P = 0.014]6.513[1.469–28.881][P = 0.046]Erythema nodosum4.139[1.374–12.492][P = 0.025]Pyoderma gangrenosum37.250[4.102-338.292][P = 0.034]32.859[6.105-176.866][P = 0.003]Aphthous ulcer6.570[1.721–25.079][P = 0.019]*A total of 55 pairwise comparisons were tested. Bonferroni correction was applied, setting the significance threshold at P < 0.0009 (0.05/55). Only associations with P < 0.0009 after correction are marked as statistically significantOdds ratios for associations involving EIMs with very small sample sizes (n < 10) should be interpreted with extreme caution due to the instability of estimates derived from small subgroups Analysis of Associations Between Different EIMs 13.271 [6.137–28.697] [P < 0.001] * 13.336 [5.584–31.849] [P < 0.001] * 4.179 [2.683–6.508] [P < 0.001] * 31.877 [8.381-121.245] [P < 0.001] * 6.316 [2.891–13.798] [P < 0.001] * 4.022 [1.497–10.808] [P = 0.014] 6.513 [1.469–28.881] [P = 0.046] 4.139 [1.374–12.492] [P = 0.025] 37.250 [4.102-338.292] [P = 0.034] 32.859 [6.105-176.866] [P = 0.003] 6.570 [1.721–25.079] [P = 0.019] *A total of 55 pairwise comparisons were tested. Bonferroni correction was applied, setting the significance threshold at P < 0.0009 (0.05/55). Only associations with P < 0.0009 after correction are marked as statistically significant Odds ratios for associations involving EIMs with very small sample sizes (n < 10) should be interpreted with extreme caution due to the instability of estimates derived from small subgroups Medication patterns observed in patients with different EIMs Medication use varied across different EIM subgroups (Table 4). The following data are descriptive only; no statistical comparisons were performed between EIM subgroups or against the no-EIM reference group. Compared to those without EIMs, IFX was used more frequently in most EIM groups, including PG (71.4%), VTE (55.2%), arthritis/arthralgia (47.0%), EN (47.6%), AS (44.7%), sacroiliitis (48.1%), and aphthous ulcer (48.4%). ADA was more commonly used in patients with SpA-related EIMs (AS 18.4%, sacroiliitis 18.5%). Glucocorticoids showed high usage in patients with VTE (72.4%), PG (57.1%), and psoriasis (55.6%). Immunosuppressants and JAK inhibitors showed no clear trends across groups, with overall low usage. Table 4Number and percentage of patients receiving different therapies, stratified by EIMsEIMsPatients(n)USTVDZIFXADAImmunosuppressantsGlucocorticoidsJAK inhibitorsWithout EIMs1868539 (28.9%)218 (11.7%)291 (15.6%)21(1.1%)308(16.5%)91(4.9%)28(1.5%)Arthritis/arthralgia18112(6.6%)39 (21.5%)85 (47.0%)12 (6.6%)30(16.6%)82(45.3%)3(1.7%)Ankylosing spondylitis382(5.3%)1(2.6%)17 (44.7%)7(18.4%)6(15.8%)15(39.5%)1(2.6%)Sacroiliitis273(11.1%)6(22.2%)13 (48.1%)5(18.5%)4(14.8%)12(44.4%)0(0.0%)Psoriasis184(22.2%)2(11.1%)7(38.9%)2(11.1%)1(5.6%)10(55.6%)0(0.0%)Erythema nodosum214(19.0%)3(14.3%)10 (47.6%)3(14.3%)5(23.8%)9(42.9%)1(4.8%)Pyoderma gangrenosum70(0.0%)2(28.6%)5(71.4%)1(14.3%)2(28.6%)4(57.1%)0(0.0%)Uveitis111(9.1%)2(18.2%)5(45.5%)0(0.0%)3(27.3%)4(36.4%)0(0.0%)Conjunctivitis81(12.5%)2(25.0%)5(62.5%)0(0.0%)1(12.5%)4(50.0%)0(0.0%)Central Retinal Vein Occlusion20(0.0%)0(0.0%)2(100%)0(0.0%)0(0.0%)1(50.0%)0(0.0%)Autoimmune hepatitis80(0.0%)4(50.0%)2(25.0%)0(0.0%)1(12.5%)5(62.5%)0(0.0%)Primary sclerosing cholangitis131(7.7%)4(30.8%)5(38.5%)0(0.0%)4(30.8%)5(38.5%)1(7.7%)Aphthous ulcer12417(13.7%)20 (16.1%)60 (48.4%)22 (17.7%)27(21.8%)58(46.8%)0(0.0%)Venous thromboembolism294(13.8%)8(27.6%)16 (55.2%)3(10.3%)6(20.7%)21(72.4%)1(3.4%)EIMs, extraintestinal manifestations; UST, ustekinumab; VDZ, vedolizumab; IFX, infliximab; ADA, adalimumab Number and percentage of patients receiving different therapies, stratified by EIMs 21 (1.1%) 308 (16.5%) 91 (4.9%) 28 (1.5%) 12 (6.6%) 30 (16.6%) 82 (45.3%) 3 (1.7%) 2 (5.3%) 1 (2.6%) 7 (18.4%) 6 (15.8%) 15 (39.5%) 1 (2.6%) 3 (11.1%) 6 (22.2%) 5 (18.5%) 4 (14.8%) 12 (44.4%) 0 (0.0%) 4 (22.2%) 2 (11.1%) 7 (38.9%) 2 (11.1%) 1 (5.6%) 10 (55.6%) 0 (0.0%) 4 (19.0%) 3 (14.3%) 3 (14.3%) 5 (23.8%) 9 (42.9%) 1 (4.8%) 0 (0.0%) 2 (28.6%) 5 (71.4%) 1 (14.3%) 2 (28.6%) 4 (57.1%) 0 (0.0%) 1 (9.1%) 2 (18.2%) 5 (45.5%) 0 (0.0%) 3 (27.3%) 4 (36.4%) 0 (0.0%) 1 (12.5%) 2 (25.0%) 5 (62.5%) 0 (0.0%) 1 (12.5%) 4 (50.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (100%) 0 (0.0%) 0 (0.0%) 1 (50.0%) 0 (0.0%) 0 (0.0%) 4 (50.0%) 2 (25.0%) 0 (0.0%) 1 (12.5%) 5 (62.5%) 0 (0.0%) 1 (7.7%) 4 (30.8%) 5 (38.5%) 0 (0.0%) 4 (30.8%) 5 (38.5%) 1 (7.7%) 17 (13.7%) 27 (21.8%) 58 (46.8%) 0 (0.0%) 4 (13.8%) 8 (27.6%) 3 (10.3%) 6 (20.7%) 21 (72.4%) 1 (3.4%) EIMs, extraintestinal manifestations; UST, ustekinumab; VDZ, vedolizumab; IFX, infliximab; ADA, adalimumab Discussion From a retrospective cross-sectional survey covering 10 clinical centers nationwide and including 2,252 hospitalized IBD patients, this study systematically delineates the epidemiological panorama of EIMs in the Chinese population. In this hospitalized cohort, the overall prevalence of EIMs was found to be 17.1%, lower than most Western studies (20%–50%) but was consistent with prevalence rates reported in other Asian populations [21]. This discrepancy may be explained by several factors [4, 22]: first, differences in racial and genetic backgrounds may lead to variations in immune response patterns. Second, environmental factors (e.g., dietary patterns, microbial exposure) may influence EIM risk by shaping unique gut microbiota and metabolic profiles. Additionally, differences in study design, diagnostic criteria, and medical record systems across countries and regions are significant factors contributing to the wide range of reported EIM prevalence and affecting cross-national comparisons. In this study, joint manifestations (10.0%) and aphthous ulcers (5.5%) were the most common, consistent with findings from Asian countries such as Japan and Korea [16–18], suggesting that joints and oral mucosa may be the most frequently involved extraintestinal sites in Asian IBD patients. In contrast, the prevalences of uveitis, PSC, and severe skin manifestations were significantly lower than those reported in Western data [5, 14, 15, 19], further supporting the existence of notable regional and population heterogeneity in EIM clinical presentations. This provides important region-specific evidence for the global management of IBD [23]. In the disease subtype analysis, the prevalence of EIMs was significantly higher in CD patients than in UC patients (20.5% vs. 15.4%), a trend consistent with similar studies [19, 24, 25]. As shown in Table 2, when aphthous ulcers were excluded from the analysis, the difference in EIM prevalence between CD and UC was no longer statistically significant (13.9% vs. 11.8%, P = 0.165). This suggests that the overall difference is largely driven by aphthous ulcers, which were disproportionately more common in CD patients (11.2% vs. 2.8%). Although the classification of aphthous ulcers as an EIM remains debated, the reasons for this specific association remain unclear and may be related to the distinct pathophysiology of CD, which involves transmural inflammation and a broader disruption of mucosal immunity [26]. Further analysis revealed that in CD patients, older age at diagnosis was associated with an increased risk of EIMs, while in UC patients, longer disease duration and a history of appendectomy were also closely related to EIM occurrence. These findings are consistent with previous studies, suggesting that patients with such characteristics should be monitored more closely and screened early in clinical practice [27]. Interestingly, the association between disease activity and EIMs in CD patients followed an unexpected pattern: mild disease activity was associated with a higher likelihood of EIMs than moderate activity (OR = 0.458), and a similar but non-significant trend was observed for severe activity (OR = 0.671). This counterintuitive finding suggests that, at least in CD, the risk of EIMs is not simply driven by the peak severity of intestinal inflammation. Existing theories support that certain EIMs—such as axial spondyloarthritis and pyoderma gangrenosum—have disease trajectories that are independent of intestinal inflammatory activity [4, 28]. Therefore, regardless of intestinal inflammatory activity, EIMs should be routinely and independently assessed. In CD patients, UST use was more common in those without EIMs. This may reflect limited subgroup sample sizes, but other factors–such as later approval of UST in China, center-specific prescribing practices, or preferential use of TNF antagonists for EIMs–cannot be excluded. In contrast, TNF antagonists, immunosuppressants, and glucocorticoids were more commonly observed in patients with EIMs. Given the cross-sectional design, reverse causality (treatment initiated for EIMs) is a likely explanation for these associations. Accordingly, these findings are reported as clinical correlates or treatment patterns, not as causal risk factors. Future prospective studies are warranted to clarify these relationships. Regarding the temporal relationship between EIMs and intestinal symptoms, this study found that 58.7% of EIMs occurred after the onset of intestinal symptoms, which is consistent with the classic hypothesis that intestinal inflammation may drive systemic manifestations [29]. However, 22.6% of patients developed EIMs before intestinal symptoms appeared, suggesting that EIMs may serve as prodromal markers of IBD, particularly providing early warning value in high-risk populations without typical gastrointestinal symptoms. The clinical identification of such patients is crucial for achieving early diagnosis and intervention in IBD and calls for increased screening awareness for IBD in non-gastroenterology specialties such as rheumatology, dermatology, and ophthalmology. Further analysis in this study revealed significant intrinsic associations between different EIMs. Arthritis/arthralgia showed strong correlations with multiple other EIMs, particularly with sacroiliitis, EN, and VTE. Additionally, strong co-occurrence was observed between PG and uveitis, as well as between PG and VTE. These findings suggest that certain EIMs may share common immunopathological bases. In clinical practice, patients presenting with one EIM should be screened for other potentially related systemic manifestations [30]. In terms of treatment patterns, this study found that IFX and glucocorticoids were widely used in most patients with EIMs, particularly in those with arthritis/arthralgia, PG, and uveitis. Their usage proportions were significantly higher than in patients without EIMs. This phenomenon aligns with the medication recommendations based on international EIM management consensus, reflecting the widespread reliance on TNF-α inhibitors and intensive anti-inflammatory therapies in clinical practice [3, 31, 32]. Notably, despite the existence of an international consensus framework, significant differences remain in the specific drug choices for different EIM subtypes. This indicates that in real-world clinical decision-making, besides adhering to guidelines, comprehensive judgments must be made based on disease activity, characteristics of the involved organs, drug accessibility, and physician experience. As a large-scale retrospective analysis based on a multicenter hospitalized population in China, this study systematically describes the epidemiological characteristics of EIMs in Chinese IBD patients and compares them with international data, providing important clinical reference value. However, the study design has certain limitations. All cases were derived from hospitalized patients, who typically present with more severe or complicated disease. This may bias the results toward a higher prevalence of EIMs compared with the general IBD population. Nevertheless, the observed prevalence (17.1%) is already lower than most Western reports, suggesting the true prevalence in Chinese IBD patients may be even lower. Therefore, our findings should be interpreted with caution regarding generalizability. Retrospective data collection is prone to information bias, and the limited sample size for rare EIMs limits statistical power. Additionally, due to the cross-sectional design, medication-EIM associations may reflect reverse causality (treatment given for EIMs) and are therefore reported as clinical correlates or descriptive patterns, not causal risk factors. Furthermore, temporal data were missing for 74 patients (19.3%) with EIMs due to unverifiable onset dates from outside records, which may introduce bias. Conclusion In this multicenter study of hospitalized patients, we observed a unique spectrum of EIMs in Chinese IBD patients, characterized by a lower reported prevalence of classic EIMs—such as articular, dermatologic, and ocular involvement—compared to Western cohorts, alongside a notably higher frequency of aphthous ulcers, particularly in Crohn’s disease. The overall prevalence of EIMs (17.1%) aligns with reported data from other Asian populations, reinforcing the role of population heterogeneity in EIM epidemiology. However, given the inpatient-only design, which may overestimate true prevalence, the actual rates in the general Chinese IBD population could be even lower than observed. The significant co-occurrence of different EIMs underscores the systemic nature of IBD and supports the practice of integrated screening when one manifestation is detected. Treatment patterns generally follow international guidelines, with TNF-α inhibitors serving as first-line therapy for most EIMs, while IL-12/23 inhibitors are increasingly used in refractory or psoriasis-associated cases. These findings, while limited by the inpatient cohort, highlight the need to develop systematic, population-tailored EIM assessment protocols and to incorporate extraintestinal evaluation into the comprehensive management of IBD in Chinese patients. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements The authors thank all patients involved in this study. We also gratefully acknowledge the clinicians and research staff at all participating centers for their dedicated work in data collection and management. This study was conducted within and supported by the MIMIC IBD Research Group and the CHASE IBD Database of China. Author contributions All authors contributed to the study conception, data acquisition, and final approval of the manuscript. Jie Liang and Liuqing Zhao led the study design and drafted the manuscript. Jun Shen, Hongliang Gao, Yanjun Chen, Xiaojing Zhao, Yan-Bo Yu, Yanyun Fan, Haitao Shi, Hailong Cao, and Linglin Tian were responsible for patient recruitment and data collection at their respective centers. All authors critically revised the manuscript. This study was conducted within and supported by the MIMIC IBD Research Group and the CHASE IBD Database of China. Funding This work was supported by grants from National Natural Science Foundation of China General Program (No. 82370588, No. 82570614), National Natural Science Foundation of China Major Research Program Integration Project (No. 92259302), the innovative medical research boosting project (XJZT25CX41), Special Project for Clinical New Technologies of Xijing Hospital (2024XJSY17, 2025XJS21). Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy and ethical restrictions. Declarations Competing interests The authors declare no competing interests. Ethics Approval This retrospective study was approved by the Ethics Committee of Xijing Hospital (Approval No. XJLL-KY-20252189). The requirement for informed consent was waived due to the retrospective nature of the study. Consent to Participate Due to the retrospective design, the need for informed consent from individual participants was waived by the ethics committee. Consent to Publish Not applicable. This manuscript does not contain any individual person’s data in any form. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy and ethical restrictions.